Sionna Stocks Plunge 92% After SION-719 Trial Fails Primary Endpoint
Sionna Therapeutics (SION) stock plunged roughly 92% on Monday after the biotech firm reported its experimental cystic fibrosis drug SION-719 failed to meet the primary endpoint in a mid-stage trial. The company announced it will not advance the drug as an add-on to existing standard care
VRTX1.47%
LucasBennett·08-10 17:27
